Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To determine, compared with Daunorubicin(DNR), whether Pegylated liposomal doxorubicin (PLD)
inducing higher complete remission (CR) rate, in untreated primary ALL adult patients with
VDCLD regimen induction therapy. Second, to determine, compared with the DNR, whether
chemotherapy containing PLD with a higher response rates and greater safety in adult ALL